Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy

Area of Science:

• Oncology
• Medical Oncology
• Soft Tissue Sarcoma Research

Background:

• Extraskeletal myxoid chondrosarcoma (EMC) is a rare, low-grade soft tissue sarcoma.
• EMC typically presents as bulky tumors in the extremities.
• Despite an initially indolent course, EMC has a high rate of distant metastasis and mortality.

Purpose of the Study:

• To review the clinical experience with extraskeletal myxoid chondrosarcoma (EMC) over three decades.
• To evaluate the efficacy of chemotherapy in patients with EMC.
• To analyze treatment outcomes and survival data for EMC patients.

Main Methods:

• Retrospective review of 11 patients with histologically confirmed EMC.
• Data collection included patient demographics, tumor characteristics, treatment regimens, and follow-up duration.
• Chemotherapy regimens primarily involved doxorubicin and dacarbazine, with some patients receiving ifosfamide or interferon.

Main Results:

• The median age of patients was 59 years, with a predominance of males (9/11).
• Most tumors (9/11) were located in the extremities and were large (median size 10 cm).
• No objective responses were observed with standard soft-tissue sarcoma chemotherapy; three patients expired, two are disease-free, and six have active disease.

Conclusions:

• Standard chemotherapy regimens, including doxorubicin, dacarbazine, and ifosfamide, demonstrate no significant efficacy in treating extraskeletal myxoid chondrosarcoma.
• The findings suggest that current chemotherapy approaches are ineffective for EMC, necessitating the exploration of alternative treatment strategies.
• Further research is required to identify novel therapeutic options for improving outcomes in patients with this rare sarcoma.